TY - JOUR
T1 - Efficacy of endoscopic ultrasound-guided hemostatic interventions for resistant nonvariceal bleeding
AU - Law, Ryan
AU - Fujii-Lau, Larissa
AU - Wong Kee Song, Louis M.
AU - Gostout, Christopher J.
AU - Kamath, Patrick S.
AU - Abu Dayyeh, Barham K.
AU - Gleeson, Ferga C.
AU - Rajan, Elizabeth
AU - Topazian, Mark D.
AU - Levy, Michael J.
N1 - Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - A subset of patients with nonvariceal gastrointestinal bleeding fail, or are unsuitable candidates for, endoscopic, radiologic, and surgical interventions. Endoscopic ultrasound (EUS)-guided intervention might be effective in these patients. We performed EUS-guided hemostatic interventions for 17 patients with nonvariceal gastrointestinal bleeding from June 2003 through May 2014 who failed, or were unsuitable candidates for, additional therapies. Indications for treatment included gastrointestinal stromal tumors, colorectal vascular malformations, duodenal masses or polyps, Dieulafoy lesions, duodenal ulcers, rectally invasive prostate cancer, pancreatic pseudoaneurysms, ulcerated esophageal cancer, and ulceration after Roux-en-Y gastric bypass. After the procedure, 88% of patients have had no further bleeding related to the treated lesion, over a median follow-up period of 12 months. EUS-guided hemostatic therapy therefore is feasible and useful for select patients with clinically severe, refractory, or recurrent nonvariceal gastrointestinal bleeding.
AB - A subset of patients with nonvariceal gastrointestinal bleeding fail, or are unsuitable candidates for, endoscopic, radiologic, and surgical interventions. Endoscopic ultrasound (EUS)-guided intervention might be effective in these patients. We performed EUS-guided hemostatic interventions for 17 patients with nonvariceal gastrointestinal bleeding from June 2003 through May 2014 who failed, or were unsuitable candidates for, additional therapies. Indications for treatment included gastrointestinal stromal tumors, colorectal vascular malformations, duodenal masses or polyps, Dieulafoy lesions, duodenal ulcers, rectally invasive prostate cancer, pancreatic pseudoaneurysms, ulcerated esophageal cancer, and ulceration after Roux-en-Y gastric bypass. After the procedure, 88% of patients have had no further bleeding related to the treated lesion, over a median follow-up period of 12 months. EUS-guided hemostatic therapy therefore is feasible and useful for select patients with clinically severe, refractory, or recurrent nonvariceal gastrointestinal bleeding.
KW - Coil Embolization
KW - Cyanoacrylate Injection
KW - Interventional Endoscopic Ultrasound
KW - Refractory GI Bleeding
UR - http://www.scopus.com/inward/record.url?scp=84924944287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924944287&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2014.09.030
DO - 10.1016/j.cgh.2014.09.030
M3 - Article
C2 - 25245627
AN - SCOPUS:84924944287
SN - 1542-3565
VL - 13
SP - 808-812.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 4
ER -